Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 1/20 | 0.59 |
| ▸ | FYN | P06241 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | HMGCR | P04035 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | TPMT | P51580 | 2/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20724883 | 0.86 | HTT (0.57) | LCKFYNHTTALDH1A1KDM4E | |
| SCHEMBL25339845 | 0.86 | LCK (0.71) | LCKFYNHTTALDH1A1KDM4E | |
| SCHEMBL30448157 | 0.86 | LCK (0.71) | LCKFYNHTTALDH1A1KDM4E | |
| SCHEMBL1918763 | 0.86 | LCK (0.66) | LCKFYNALDH1A1KDM4EHPGD | |
| SCHEMBL4466238 | 0.85 | HTT (0.72) | LCKFYNHTTALDH1A1KDM4E | |
| Hydrochloric Acid SCHEMBL4409779 | 0.85 | LCK (0.63) | LCKFYNALDH1A1KDM4EHPGD | |
| SCHEMBL1038769 | 0.84 | HTT (0.70) | LCKFYNHTTALDH1A1KDM4E | |
| SCHEMBL28252586 | 0.84 | HTT (0.70) | LCKFYNHTTALDH1A1KDM4E | |
| SCHEMBL15074289 | 0.84 | HTT (0.50) | LCKFYNHTTALDH1A1KDM4E | |
| SCHEMBL10692871 | 0.84 | HTT (0.50) | LCKFYNHTTALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114146071-B | Application of paeonol and its derivatives in preventing and treating leukoplakia syndrome | 西北农林科技大学深圳研究院 | 2023-02-28 | — | — | CN | claimed |
| CN-114146071-A | Application of paeonol and its derivatives in preventing and treating leukoplakia syndrome | 西北农林科技大学深圳研究院 | 2022-03-08 | — | — | CN | claimed |
| US-20260092052-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2026-04-02 | — | — | US | disclosed |
| US-20240109874-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2024-04-04 | — | — | US | disclosed |
| CN-114146071-B | Application of paeonol and its derivatives in preventing and treating leukoplakia syndrome | 西北农林科技大学深圳研究院 | 2023-02-28 | — | — | CN | disclosed |
| US-20220411413-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2022-12-29 | — | — | US | disclosed |
| US-20220315565-A1 | INHIBITING FATTY ACID SYNTHASE (FASN) | FORMA THERAPEUTICS, INC. | 2022-10-06 | — | — | US | disclosed |
| CN-115040497-A | Application of paeonol derivative in preventing and treating leukoplakia syndrome | 西北农林科技大学深圳研究院 | 2022-09-13 | — | — | CN | disclosed |
| US-11299484-B2 | Inhibiting fatty acid synthase (FASN) | FORMA THERAPEUTICS, INC. (US) | 2022-04-12 | — | — | US | disclosed |
| CN-114146071-A | Application of paeonol and its derivatives in preventing and treating leukoplakia syndrome | 西北农林科技大学深圳研究院 | 2022-03-08 | — | — | CN | disclosed |
| CN-113329748-A | Inhibition of Fatty Acid Synthase (FASN) | 福马治疗股份有限公司 | 2021-08-31 | — | — | CN | disclosed |
| US-9399645-B2 | Inhibitors of HIV replication | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-07-26 | — | — | US | disclosed |
| US-20160152598-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL (JP) | 2016-06-02 | — | — | US | disclosed |
| US-20160152603-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL (JP) | 2016-06-02 | — | — | US | disclosed |
| US-9315458-B2 | Nitrogen-containing heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY, LIMITED (JP) | 2016-04-19 | — | — | US | disclosed |
| US-20150307451-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-10-29 | — | — | US | disclosed |
| WO-2015163485-A1 | ISOINDOLINE-1-ONE DERIVATIVES AS CHOLINERGIC MUSCARINIC M1 RECEPTOR POSITIVE ALLOESTERIC MODULATOR ACTIVITY FOR THE TREATMENT OF ALZHEIMERS DISEASE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-10-29 | — | — | WO | disclosed |
| EP-2069280-B1 | Process and intermediates for preparing HIV integrase inhibitors | GILEAD SCIENCES INC (US) | 2015-03-25 | — | — | EP | disclosed |
| US-20150011531-A1 | INHIBITORS OF HIV REPLICATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-01-08 | — | — | US | disclosed |
| WO-2013091096-A1 | CONDENSED TRICLYCLIC COMPOUNDS AS INHIBITORS OF HIV REPLICATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160152598-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | CHRM1, CHRM5, CHRM2 | LCK 1827/4885FYN 173/4885HTT 247/4885 |
| US-20160152603-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | CHRM1, CHRM5, CHRM2 | LCK 1827/4885FYN 173/4885HTT 247/4885 |
| US-20240109874-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | CHRM1, CHRM5, CHRM2 | LCK 1827/4885FYN 173/4885HTT 247/4885 |
| US-20260092052-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | CHRM1, CHRM2, CHRM4 | LCK 1501/4885FYN 266/4885HTT 370/4885 |
| US-20220411413-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | CHRM1, CHRM5, CHRM2 | LCK 1827/4885FYN 173/4885HTT 247/4885 |
| US-20150307451-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | CHRM1, CHRM5, CHRM2 | LCK 1827/4885FYN 173/4885HTT 247/4885 |
| US-20220315565-A1 | INHIBITING FATTY ACID SYNTHASE (FASN) | FASN, SCD, FADS1 | LCK 2914/4885FYN 1927/4885HTT 2196/4885 |
| US-20150011531-A1 | INHIBITORS OF HIV REPLICATION | MCM3, REV1, POLR2E | LCK 2023/4885FYN 2317/4885HTT 3583/4885 |
| US-11299484-B2 | Inhibiting fatty acid synthase (FASN) | FASN, SCD, FADS1 | LCK 2914/4885FYN 1927/4885HTT 2196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.